TWI565703B - 2-(1,2,3-三唑-2-基)苯甲醯胺及3-(1,2,3-三唑-2-基)吡啶醯胺衍生物 - Google Patents

2-(1,2,3-三唑-2-基)苯甲醯胺及3-(1,2,3-三唑-2-基)吡啶醯胺衍生物 Download PDF

Info

Publication number
TWI565703B
TWI565703B TW105118634A TW105118634A TWI565703B TW I565703 B TWI565703 B TW I565703B TW 105118634 A TW105118634 A TW 105118634A TW 105118634 A TW105118634 A TW 105118634A TW I565703 B TWI565703 B TW I565703B
Authority
TW
Taiwan
Prior art keywords
triazol
benzyl
phenyl
methyl
morpholin
Prior art date
Application number
TW105118634A
Other languages
English (en)
Chinese (zh)
Other versions
TW201632517A (zh
Inventor
馬汀 波利
克里斯多夫 博斯
克利斯汀 布洛奇
畢比雅 海曼
賽瑞 席佛林
喬帝T 威廉斯
Original Assignee
艾克泰聯製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 艾克泰聯製藥有限公司 filed Critical 艾克泰聯製藥有限公司
Publication of TW201632517A publication Critical patent/TW201632517A/zh
Application granted granted Critical
Publication of TWI565703B publication Critical patent/TWI565703B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TW105118634A 2011-11-08 2012-11-07 2-(1,2,3-三唑-2-基)苯甲醯胺及3-(1,2,3-三唑-2-基)吡啶醯胺衍生物 TWI565703B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2011054976 2011-11-08

Publications (2)

Publication Number Publication Date
TW201632517A TW201632517A (zh) 2016-09-16
TWI565703B true TWI565703B (zh) 2017-01-11

Family

ID=47258050

Family Applications (2)

Application Number Title Priority Date Filing Date
TW105118634A TWI565703B (zh) 2011-11-08 2012-11-07 2-(1,2,3-三唑-2-基)苯甲醯胺及3-(1,2,3-三唑-2-基)吡啶醯胺衍生物
TW101141421A TWI555747B (zh) 2011-11-08 2012-11-07 2-(1,2,3-三唑-2-基)苯甲醯胺及3-(1,2,3-三唑-2-基)吡啶醯胺衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW101141421A TWI555747B (zh) 2011-11-08 2012-11-07 2-(1,2,3-三唑-2-基)苯甲醯胺及3-(1,2,3-三唑-2-基)吡啶醯胺衍生物

Country Status (28)

Country Link
US (1) US9150566B2 (cg-RX-API-DMAC7.html)
EP (1) EP2776430B1 (cg-RX-API-DMAC7.html)
JP (1) JP5718535B2 (cg-RX-API-DMAC7.html)
KR (1) KR101676930B1 (cg-RX-API-DMAC7.html)
CN (1) CN103917538B (cg-RX-API-DMAC7.html)
AR (1) AR088692A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012335194B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014010617B1 (cg-RX-API-DMAC7.html)
CA (1) CA2846568C (cg-RX-API-DMAC7.html)
CL (1) CL2014000659A1 (cg-RX-API-DMAC7.html)
CY (1) CY1117638T1 (cg-RX-API-DMAC7.html)
DK (1) DK2776430T3 (cg-RX-API-DMAC7.html)
EA (1) EA024106B1 (cg-RX-API-DMAC7.html)
ES (1) ES2572703T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160678T1 (cg-RX-API-DMAC7.html)
HU (1) HUE029239T2 (cg-RX-API-DMAC7.html)
IL (1) IL232462A (cg-RX-API-DMAC7.html)
IN (1) IN2014CN04127A (cg-RX-API-DMAC7.html)
MX (1) MX343837B (cg-RX-API-DMAC7.html)
MY (1) MY167791A (cg-RX-API-DMAC7.html)
PH (1) PH12014500852A1 (cg-RX-API-DMAC7.html)
PL (1) PL2776430T3 (cg-RX-API-DMAC7.html)
SG (1) SG11201401665WA (cg-RX-API-DMAC7.html)
SI (1) SI2776430T1 (cg-RX-API-DMAC7.html)
TW (2) TWI565703B (cg-RX-API-DMAC7.html)
UA (1) UA112317C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013068935A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201404189B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
CA2863413A1 (en) 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
CN104334544B (zh) 2012-06-04 2016-10-19 埃科特莱茵药品有限公司 苯并咪唑脯氨酸衍生物
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
SI3077389T1 (en) 2013-12-03 2018-01-31 Idorsia Pharmaceuticals Ltd (S) - (2- (6-CHLORO-7-METHYL-1 H-BENZO (D) IMIDAZOL-2-YL) -2-METHYLPYROLIDIN-1-YL (5-METHOXY-2- (2H- , 2,3-TRIAZOL-2-IL) PHENYL) METHANONE AND ITS USE AS ANTAGONISTS OF OREXIN RECEPTOR
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
CA2930053A1 (en) 2013-12-04 2015-06-11 Actelion Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
JP2017024990A (ja) * 2013-12-13 2017-02-02 大正製薬株式会社 オキサゾリジン及びオキサジナン誘導体
JP5907310B2 (ja) * 2013-12-13 2016-04-26 大正製薬株式会社 オキサジナン化合物の結晶形及びその製造方法
EP3143999A4 (en) * 2014-05-16 2017-12-20 The University of Tokyo Depression treatment agent
EP3180332B1 (en) 2014-08-13 2021-10-27 Eolas Therapeutics Inc. Difluoropyrrolidines as orexin receptor modulators
WO2016095205A1 (en) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Heteroaryl orexin receptor antagonists
CN104557744B (zh) * 2014-12-23 2017-04-12 广东东阳光药业有限公司 一种三氮唑化合物的制备方法
JP6936224B2 (ja) 2015-11-23 2021-09-15 サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. オクタヒドロピロロ[3,4−c]ピロール誘導体およびその使用
EA036542B9 (ru) 2016-02-12 2020-12-22 Астразенека Аб Галоген-замещенные пиперидины в качестве модуляторов орексинового рецептора
EP3619199B1 (en) 2017-05-03 2021-07-07 Idorsia Pharmaceuticals Ltd Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives
WO2020099511A1 (en) * 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
GB201901142D0 (en) 2019-01-28 2019-03-20 Heptares Therapeutics Ltd OX1 Antagonists
CN116724037A (zh) * 2021-02-02 2023-09-08 爱杜西亚药品有限公司 (4-甲基-2-[1,2,3]三唑-2-基-苯基)-[(r)-3-(3-[1,2,3]三唑-2-基-苄基)-吗啉-4-基]-甲酮的结晶形式
AR129309A1 (es) * 2022-05-13 2024-08-07 Idorsia Pharmaceuticals Ltd Derivados de hidrazina-n-carboxamida cíclica sustituida con tiazoloaril-metilo
CN115947697A (zh) * 2022-12-28 2023-04-11 苏州汉德创宏生化科技有限公司 一种3-氧代吗啉-4-羧酸叔丁酯的合成方法
TW202441289A (zh) * 2023-04-10 2024-10-16 日商三菱瓦斯化學股份有限公司 化合物、組成物、表現增感效果的方法及製造方法
GB202311281D0 (en) 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists
GB202311280D0 (en) 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002559A2 (en) * 2001-06-28 2003-01-09 Smithkline Beecham P.L.C. Piperidine compounds for use as orexin receptor antagonist

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130432A (en) 1990-12-21 1992-07-14 Syntex (U.S.A.) Inc. Process for preparing cyclic amines and intermediate products thereof
PT100639A (pt) 1991-06-27 1993-09-30 Univ Virginia Commonwealth Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina
EP1435955A2 (en) * 2001-05-05 2004-07-14 SmithKline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
CN1549816A (zh) 2001-06-28 2004-11-24 ʷ 作为阿立新受体拮抗药的n-芳酰基环胺衍生物
GB0124463D0 (en) * 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0130335D0 (en) * 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
CN1926109B (zh) 2004-03-01 2011-04-13 埃科特莱茵药品有限公司 经取代的1,2,3,4-四氢异喹啉衍生物
AU2007226203A1 (en) 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
AU2007272854B2 (en) 2006-07-14 2013-08-01 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
GB0620818D0 (en) 2006-10-19 2006-11-29 Ucb Sa Therapeutic agents
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
EP2207778A2 (en) 2007-09-24 2010-07-21 Actelion Pharmaceuticals Ltd. Pyrrolidines and piperidines as orexin receptor antagonists
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
US8669272B2 (en) * 2008-10-21 2014-03-11 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
US8466281B2 (en) * 2008-10-21 2013-06-18 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
EP2349269A4 (en) 2008-10-21 2012-04-25 Merck Sharp & Dohme 2,5-DISUBSTITUTED PIPERIDINOREXINE RECEPTOR ANTAGONISTS
AU2009324239A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
TW201031407A (en) 2008-12-02 2010-09-01 Glaxo Group Ltd Novel compounds
WO2011050200A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
MX2012004753A (es) 2009-10-23 2012-09-07 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirrolos disustituidos como moduladores del receptor de orexina.
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002559A2 (en) * 2001-06-28 2003-01-09 Smithkline Beecham P.L.C. Piperidine compounds for use as orexin receptor antagonist

Also Published As

Publication number Publication date
CA2846568C (en) 2020-01-14
JP2014532753A (ja) 2014-12-08
US20150158855A1 (en) 2015-06-11
TWI555747B (zh) 2016-11-01
ZA201404189B (en) 2017-08-30
EA201400553A1 (ru) 2014-10-30
MX343837B (es) 2016-11-24
PL2776430T3 (pl) 2016-09-30
TW201323421A (zh) 2013-06-16
MY167791A (en) 2018-09-26
UA112317C2 (uk) 2016-08-25
ES2572703T3 (es) 2016-06-01
HUE029239T2 (en) 2017-02-28
CL2014000659A1 (es) 2014-08-18
CN103917538B (zh) 2016-08-24
EP2776430B1 (en) 2016-03-16
EP2776430A1 (en) 2014-09-17
CN103917538A (zh) 2014-07-09
IN2014CN04127A (cg-RX-API-DMAC7.html) 2015-07-10
PH12014500852A1 (en) 2016-03-02
SG11201401665WA (en) 2014-09-26
US9150566B2 (en) 2015-10-06
WO2013068935A1 (en) 2013-05-16
KR101676930B1 (ko) 2016-11-16
BR112014010617A2 (pt) 2017-04-25
NZ625896A (en) 2016-04-29
HK1199022A1 (zh) 2015-06-19
IL232462A (en) 2016-11-30
AU2012335194B2 (en) 2017-05-25
KR20140096338A (ko) 2014-08-05
MX2014005635A (es) 2014-06-23
EA024106B1 (ru) 2016-08-31
IL232462A0 (en) 2014-06-30
CA2846568A1 (en) 2013-05-16
BR112014010617A8 (pt) 2017-12-26
JP5718535B2 (ja) 2015-05-13
BR112014010617B1 (pt) 2021-12-14
AR088692A1 (es) 2014-06-25
SI2776430T1 (sl) 2016-06-30
HRP20160678T1 (hr) 2016-07-15
TW201632517A (zh) 2016-09-16
CY1117638T1 (el) 2017-04-26
DK2776430T3 (en) 2016-05-09
AU2012335194A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
TWI565703B (zh) 2-(1,2,3-三唑-2-基)苯甲醯胺及3-(1,2,3-三唑-2-基)吡啶醯胺衍生物
CN104703980B (zh) 属于[邻双(杂)芳基]‑[2‑(间双(杂)芳基)吡咯烷‑1‑基]甲酮衍生物的食欲素受体拮抗剂
TWI639595B (zh) 作為LRRK2(富含白胺酸重複激酶2)抑制劑之新穎咪唑並[4,5-c]喹啉和咪唑並[4,5-c][1,5]萘啶衍生物
TWI570120B (zh) 苯并咪唑脯胺酸衍生物
CN106117193B (zh) 新的杂环衍生物及其在神经性疾病治疗中的应用
KR102169426B1 (ko) 신규 피라졸 유도체
MX2008014796A (es) Derivados de aril-4-etinil-isoxazol.
TW201639851A (zh) 雙環咪唑衍生物
KR20140051922A (ko) 페닐-3-아자-바이사이클로[3.1.0]헥스-3일-메타논 및 약제로서의 이의 용도
US9403813B2 (en) Azetidine amide derivatives as orexin receptor antagonists
WO2020007964A1 (en) 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
HK1199022B (en) 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists
WO2023218023A1 (en) Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives
NZ625896B2 (en) 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists
TW202438055A (zh) 用於處置高血糖及高血糖為特徵的疾患之取代羥甲基吡咯啶類

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees